Xenia Ganz

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 2.8K citations · Full text

Metabolic Syndrome, Diabetes Management, Cardiovascular Disease +9

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 600 citations · Full text

Metabolic Syndrome, Diabetes Management, Urology +10

Relationship Between Hypoglycemic Episodes and Ventricular Arrhythmias in Patients With Type 2 Diabetes and Cardiovascular Diseases: Silent Hypoglycemias and Silent Arrhythmias

Frank Pistrosch, Xenia Ganz, Madlen Teige et al. · Diabetes Care · 2013 · 172 citations · Full text

Risk of and risk factors for hypoglycemia and associated arrhythmias in patients with type 2 diabetes and cardiovascular disease: a cohort study under real-world conditions

Frank Pistrosch, Xenia Ganz, Stefan R. Bornstein et al. · Acta Diabetologica · 2015 · 73 citations · Full text

Diabetes Epidemiology, Cardiovascular Epidemiology, Cardiovascular Disease +11

Serum and Plasma Levels of Vascular Endothelial Growth Factors in Relation to Quality of Glucose Control, Biomarkers of Inflammation, and Diabetic Nephropathy

M Hanefeld, Dieter Appelt, Katrin Engelmann et al. · Hormone and Metabolic Research · 2016 · 34 citations

Serum Vegf-a, Vascular Disease, Glucose Control +22